LU92446I2 - Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium - Google Patents

Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium

Info

Publication number
LU92446I2
LU92446I2 LU92446C LU92446C LU92446I2 LU 92446 I2 LU92446 I2 LU 92446I2 LU 92446 C LU92446 C LU 92446C LU 92446 C LU92446 C LU 92446C LU 92446 I2 LU92446 I2 LU 92446I2
Authority
LU
Luxembourg
Prior art keywords
dolutegravir
solvate
pharmaceutically acceptable
acceptable salt
including sodium
Prior art date
Application number
LU92446C
Other languages
English (en)
French (fr)
Original Assignee
Shionogi & Co
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92446(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co, Viiv Healthcare Co filed Critical Shionogi & Co
Publication of LU92446I2 publication Critical patent/LU92446I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU92446C 2005-04-28 2014-05-07 Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium LU92446I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JP2005312076 2005-10-27
PCT/US2006/016604 WO2006116764A1 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Publications (1)

Publication Number Publication Date
LU92446I2 true LU92446I2 (fr) 2015-10-29

Family

ID=37215098

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92446C LU92446I2 (fr) 2005-04-28 2014-05-07 Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium
LU00210C LUC00210I2 (de) 2005-04-28 2021-06-15

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU00210C LUC00210I2 (de) 2005-04-28 2021-06-15

Country Status (29)

Country Link
US (21) US8129385B2 (de)
EP (9) EP3045206B2 (de)
JP (2) JP4295353B2 (de)
KR (4) KR101580310B1 (de)
AU (1) AU2006239177B8 (de)
BR (1) BRPI0610030B8 (de)
CA (1) CA2606282C (de)
CY (6) CY1115151T1 (de)
DK (6) DK3372281T3 (de)
EA (1) EA014162B1 (de)
ES (7) ES2437268T3 (de)
FI (1) FIC20210017I1 (de)
FR (1) FR14C0041I2 (de)
HK (4) HK1107227A1 (de)
HU (6) HUE037795T2 (de)
IL (4) IL186555A (de)
LT (4) LT3372281T (de)
LU (2) LU92446I2 (de)
MA (1) MA29460B1 (de)
MX (2) MX302718B (de)
NL (2) NL300676I2 (de)
NO (5) NO339525B1 (de)
NZ (1) NZ562339A (de)
PL (5) PL3372281T3 (de)
PT (5) PT3372281T (de)
SI (6) SI2465580T1 (de)
TW (1) TWI378931B (de)
VN (1) VN34404A1 (de)
WO (1) WO2006116764A1 (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5384793B2 (ja) 2003-12-24 2014-01-08 バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド 呼吸器合胞体ウイルス感染の処置のための多環式薬剤
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
LT3372281T (lt) * 2005-04-28 2021-12-10 Viiv Healthcare Company Policiklinis karbamoilpiridono darinys, turintis živ integrazės inhibitorinį aktyvumą
WO2006121831A2 (en) 2005-05-10 2006-11-16 Merck & Co., Inc. Hiv integrase inhibitors
US7939537B2 (en) 2005-10-04 2011-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HIV integrase inhibitors
TW200800988A (en) 2005-10-27 2008-01-01 Shionogi & Amp Co Ltd Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
RU2503679C2 (ru) * 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
CA2705318C (en) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
JP5285709B2 (ja) 2007-11-16 2013-09-11 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
US8217034B2 (en) 2008-07-25 2012-07-10 Shionogi & Co., Ltd. Chemical compounds
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011814A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
US8183372B2 (en) 2008-07-25 2012-05-22 Shionogi & Co., Ltd. Substituted 9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydor-1H-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazines
US8624023B2 (en) * 2008-12-11 2014-01-07 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
CN102239155A (zh) * 2008-12-11 2011-11-09 盐野义制药株式会社 生产麦芽糖醇醚的方法和中间体
CN104788367A (zh) 2008-12-11 2015-07-22 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
EP2444400B1 (de) * 2009-06-15 2018-03-28 Shionogi&Co., Ltd. Substituiertes polyzyklisches carbamoylpyridonderivat
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
US8497270B2 (en) 2009-10-13 2013-07-30 Elanco Animal Health Ireland Limited Macrocyclic integrase inhibitors
ES2969969T3 (es) * 2010-01-27 2024-05-23 Viiv Healthcare Co Combinaciones de dolutegravir y lamivudina para el tratamiento de la infección por VIH
AU2014202405B2 (en) * 2010-01-27 2016-02-25 Viiv Healthcare Company Antiviral therapy
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
TWI508968B (zh) 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
EP2540720B1 (de) * 2010-02-26 2015-04-15 Japan Tobacco, Inc. 1,3,4,8-tetrahydro-2h-pyrido-[1,2-a]pyrazinderivat und verwendung davon als hiv-integrase-hemmer
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
EP2552923B1 (de) 2010-04-02 2014-03-26 Janssen R&D Ireland Makrocyclische integraseinhibitoren
JP5766690B2 (ja) * 2010-04-12 2015-08-19 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
EP3456721B1 (de) 2010-08-05 2021-02-24 Shionogi & Co., Ltd Verfahren zur herstellung von verbindungen mit hiv-integrase-hemmender wirkung
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
RU2608519C2 (ru) * 2010-09-24 2017-01-19 Шионоги энд Ко. Лтд. Пролекарственная форма замещенного полициклического производного карбамоилпиридона
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
EP2742051B1 (de) * 2011-09-14 2016-10-12 Mapi Pharma Limited Amorphe Form des Dolutegravir Natrium Salzes
WO2013054862A1 (ja) 2011-10-12 2013-04-18 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
CA2860323C (en) 2011-12-28 2022-03-08 The Regents Of The University Of California Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
DK3608325T3 (da) * 2012-12-21 2022-08-22 Gilead Sciences Inc Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
WO2014104279A1 (ja) 2012-12-27 2014-07-03 日本たばこ産業株式会社 置換されたスピロピリド［１，２－ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途
EP2956123A1 (de) 2013-02-18 2015-12-23 ratiopharm GmbH Feste pharmazeutische darreichungsform von dolutegravir
EP2767272A1 (de) 2013-02-18 2014-08-20 Ratiopharm GmbH Feste pharmazeutische Darreichungsform von Dolutegravir
US9573965B2 (en) 2013-02-19 2017-02-21 Aurobindo Pharma Ltd Process for the preparation of Dolutegravir
AU2014237348C1 (en) 2013-03-15 2019-02-07 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG11201507453VA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20160083343A1 (en) 2013-03-15 2016-03-24 Global Blood Therapeutics, Inc Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
EP3008044B1 (de) * 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Kondensierte tricyclische heterocyclische verbindungen als hiv-integrase-hemmer
EP3016935B1 (de) * 2013-07-04 2018-09-05 Hetero Research Foundation Verfahren zur herstellung eines dolutegravir-zwischenprodukts
NO2865735T3 (de) 2013-07-12 2018-07-21
EP3019503B1 (de) 2013-07-12 2017-09-06 Gilead Sciences, Inc. Polycyclische-carbamoylpyridon-verbindungen und deren verwendung zur behandlung von hiv-infektionen
EP3022209B1 (de) 2013-07-17 2018-03-07 ratiopharm GmbH Dolutegravir-kaliumsalz
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EA030695B1 (ru) 2013-09-27 2018-09-28 Мерк Шарп И Доум Корп. Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015089847A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2015110897A2 (en) * 2014-01-21 2015-07-30 Laurus Labs Private Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
MY189995A (en) 2014-02-07 2022-03-22 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN106831819B (zh) * 2014-03-19 2019-01-04 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
ZA201503540B (en) * 2014-05-20 2016-10-26 Cipla Ltd Process for preparing polycyclic carbamoyl pyridone derivatives
NO2717902T3 (de) 2014-06-20 2018-06-23
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US10011613B2 (en) 2014-08-22 2018-07-03 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
EP3203995A4 (de) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska Zusammensetzungen und verfahren zur abgabe von therapiemitteln
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016102078A1 (en) 2014-12-24 2016-06-30 Ratiopharm Gmbh Solid state forms of dolutegravir sodium
EP3045461A1 (de) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Verfahren zur Herstellung Dolutegravir und Analoga davon
KR20170113650A (ko) 2015-02-06 2017-10-12 밀란 래버러토리스 리미티드 돌루테그라비어의 제조 방법
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
EP3285582B1 (de) * 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Phosphatsubstituierte chinolizinderivate als hiv-integrase-hemmer
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
SI3466490T1 (sl) * 2015-04-02 2020-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
MD3428170T2 (ro) * 2015-04-28 2021-06-30 Shionogi & Co Derivat de piridonă policiclică anti-gripal și promedicament al acestuia
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
EP3337479B1 (de) 2015-08-19 2023-12-13 Laurus Labs Limited Neuartige polymorphe aus dolutegravir und salze davon
SG11201802983TA (en) 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
PT3394069T (pt) 2015-12-21 2019-08-30 Lupin Ltd Processo para a preparação de inibidores de integrase de vih
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
EP4299133A3 (de) * 2016-06-23 2024-03-13 VIIV Healthcare Company Zusammensetzungen und verfahren zur abgabe von therapiemitteln
BR112019002120A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
EP3496718A4 (de) 2016-08-08 2020-01-22 Hetero Labs Limited Antiretrovirale zusammensetzungen
CN109789144B (zh) * 2016-08-12 2022-04-15 马德拉医疗公司 蛋白激酶调节剂
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018057408A1 (en) * 2016-09-21 2018-03-29 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JP2020500866A (ja) 2016-12-02 2020-01-16 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
EP3363802B1 (de) * 2017-02-16 2019-11-20 Sandoz AG Krystalline form von cabotegravir natriumsalz
AU2018221379B2 (en) 2017-02-16 2021-11-04 ViiV Healthcare UK (No.3) Limited Crystalline forms of cabotegravir sodium
EP3655106A4 (de) * 2017-07-18 2021-04-21 VIIV Healthcare Company Kombinationswirkstofftherapie
CN117298114A (zh) 2017-07-21 2023-12-29 Viiv保健公司 用于治疗hib感染和aids的方案
EP3661940A1 (de) 2017-09-07 2020-06-10 Cipla Limited Neue polymorphe von dolutegravirnatrium
JP6924839B2 (ja) 2017-10-06 2021-08-25 塩野義製薬株式会社 置換された多環性ピリドン誘導体の立体選択的な製造方法
US11839623B2 (en) 2018-01-12 2023-12-12 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
AR115455A1 (es) 2018-05-31 2021-01-20 Shionogi & Co Derivado de piridotriazina policíclica
TW202402756A (zh) * 2018-05-31 2024-01-16 日商鹽野義製藥股份有限公司 多環性吡啶并三𠯤衍生物
EA202092923A1 (ru) 2018-05-31 2021-04-09 Сионоги Энд Ко., Лтд. Полициклическое производное пиридона
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
SG11202104117WA (en) 2018-10-22 2021-05-28 Univ Nebraska Antiviral prodrugs and nanoformulations thereof
SG11202109650XA (en) 2019-03-22 2021-10-28 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
US20230045509A1 (en) 2019-12-09 2023-02-09 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
US11697652B2 (en) * 2020-02-24 2023-07-11 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2022051198A1 (en) 2020-09-01 2022-03-10 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
JP2024500322A (ja) 2020-12-07 2024-01-09 ヴィーブ、ヘルスケア、カンパニー 併用療法
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
WO2022253294A1 (zh) 2021-06-03 2022-12-08 江苏恒瑞医药股份有限公司 具有整合酶抑制活性的吡啶酮化合物及其药用用途
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023102374A1 (en) 2021-12-03 2023-06-08 Viiv Healthcase Company Process of synthesizing (r)-3-aminobutan-1-ol

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
CA2309882A1 (en) 1997-12-22 1999-07-01 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
US20040039060A1 (en) † 2000-06-14 2004-02-26 Ryuichi Kiyama Inhibitor for enzyme having two divalent metal ions as active centers
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
JP4287649B2 (ja) 2000-10-12 2009-07-01 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
US20040229909A1 (en) 2001-08-10 2004-11-18 Ryuichi Kiyama Antiviral agent
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
JP3927175B2 (ja) 2001-10-26 2007-06-06 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｎ−置換ヒドロキシピリミジノンカルボキサミド系ｈｉｖインテグラーゼ阻害薬
JP4523281B2 (ja) 2002-01-17 2010-08-11 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7358249B2 (en) 2002-08-13 2008-04-15 Shionogi & Co., Ltd. Heterocyclic compounds having inhibitory activity against HIV integrase
EP1549315A4 (de) * 2002-09-11 2007-05-23 Merck & Co Inc Dihydroxypyridopyrazin-1,6-dion-verbindungen als hiv-integrase-inhibitoren
KR20050087865A (ko) * 2002-12-27 2005-08-31 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. ＨＩＶ 인테그라제 억제제로서 유용한테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘 및 관련화합물
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
WO2004101512A2 (en) 2003-05-13 2004-11-25 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
AU2003273190A1 (en) * 2003-08-12 2005-02-25 Rachel Beijer Scheduled message service
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
US8691991B2 (en) 2004-02-11 2014-04-08 Shionogi & Co., Ltd. 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors
JP2007528379A (ja) 2004-03-09 2007-10-11 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｈｉｖインテグラーゼ阻害薬
CN1929737A (zh) † 2004-03-09 2007-03-14 默克公司 Hiv整合酶抑制剂
EP1756114B1 (de) 2004-05-07 2014-11-19 Merck Sharp & Dohme Corp. Hiv-integrasehemmer
CA2634499A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
JP5317257B2 (ja) * 2005-02-21 2013-10-16 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
AU2006228278C1 (en) 2005-03-31 2011-06-23 Msd Italia S.R.L. HIV integrase inhibitors
LT3372281T (lt) * 2005-04-28 2021-12-10 Viiv Healthcare Company Policiklinis karbamoilpiridono darinys, turintis živ integrazės inhibitorinį aktyvumą
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
US20080214527A1 (en) 2005-08-04 2008-09-04 Takashi Kawasuji Hiv Integrase Inhibitors
TW200800988A (en) 2005-10-27 2008-01-01 Shionogi & Amp Co Ltd Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity

Also Published As

Publication number Publication date
IL215788A0 (en) 2011-12-29
EP3187225A1 (de) 2017-07-05
EP2527007B1 (de) 2016-03-30
HK1251191A1 (zh) 2019-01-25
EA014162B1 (ru) 2010-10-29
SI1874117T1 (sl) 2014-01-31
US20170029438A1 (en) 2017-02-02
ES2437268T3 (es) 2014-01-09
US20190152990A1 (en) 2019-05-23
NL301109I2 (nl) 2021-09-15
BRPI0610030B1 (pt) 2020-09-15
NO2023042I1 (no) 2023-11-08
KR20080009733A (ko) 2008-01-29
LT3372281T (lt) 2021-12-10
US8129385B2 (en) 2012-03-06
EP3284520B1 (de) 2019-06-05
SI3187225T1 (sl) 2022-04-29
JP2009079058A (ja) 2009-04-16
KR101363875B1 (ko) 2014-02-21
PL1874117T3 (pl) 2014-01-31
US20160304535A1 (en) 2016-10-20
US8778943B2 (en) 2014-07-15
AU2006239177B2 (en) 2011-10-20
CY1120345T1 (el) 2019-07-10
CY1122052T1 (el) 2020-10-14
EP2527007A1 (de) 2012-11-28
ES2892304T3 (es) 2022-02-03
EP3372281B1 (de) 2021-07-07
NO20075165L (no) 2007-11-22
AU2006239177A1 (en) 2006-11-02
EP1874117A1 (de) 2008-01-09
HUE056603T2 (hu) 2022-02-28
KR101848819B1 (ko) 2018-04-16
PT1874117E (pt) 2013-10-17
CY2014024I1 (el) 2015-12-09
PL2465580T3 (pl) 2014-05-30
EP3284519A1 (de) 2018-02-21
NZ562339A (en) 2011-01-28
MX312216B (en) 2013-08-12
HUS1400039I1 (hu) 2016-08-29
EP2465580B1 (de) 2013-12-18
EP1874117A4 (de) 2009-12-30
US20220213121A1 (en) 2022-07-07
NO2017010I2 (no) 2017-03-27
EP3284519A8 (de) 2018-04-18
NO340111B1 (no) 2017-03-13
US20090318421A1 (en) 2009-12-24
TW200716635A (en) 2007-05-01
EP1874117B1 (de) 2013-08-28
EP1874117B8 (de) 2014-03-12
EP3187225B1 (de) 2022-01-05
CA2606282A1 (en) 2006-11-02
ES2567197T3 (es) 2016-04-20
PT3372281T (pt) 2021-10-14
US8410103B2 (en) 2013-04-02
MX302718B (es) 2012-08-27
IL186555A (en) 2016-10-31
IL225206A (en) 2017-11-30
PT3045206T (pt) 2018-07-05
DK3045206T3 (en) 2018-05-22
HK1107227A1 (en) 2008-04-03
EP3187226A1 (de) 2017-07-05
US20140200209A1 (en) 2014-07-17
US20160137666A1 (en) 2016-05-19
EP2465580A1 (de) 2012-06-20
US9273065B2 (en) 2016-03-01
EP3045206A1 (de) 2016-07-20
IL186555A0 (en) 2008-01-20
CY1115151T1 (el) 2015-12-09
HK1172282A1 (en) 2013-04-19
EP3284520A1 (de) 2018-02-21
ES2906792T3 (es) 2022-04-20
LTC2465580I2 (de) 2022-10-10
HUE037795T2 (hu) 2018-09-28
LT3284520T (lt) 2019-09-25
LTPA2021512I1 (de) 2021-07-12
FR14C0041I1 (de) 2014-06-27
HUS2100023I1 (hu) 2021-07-28
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
US20170224695A1 (en) 2017-08-10
FIC20210017I1 (fi) 2021-06-10
EP3045206B1 (de) 2018-03-28
MA29460B1 (fr) 2008-05-02
AU2006239177B8 (en) 2012-02-16
US20170145033A1 (en) 2017-05-25
NO2017010I1 (no) 2017-03-27
HUE044978T2 (hu) 2019-11-28
TWI378931B (en) 2012-12-11
NL300676I2 (de) 2016-10-11
BRPI0610030A2 (pt) 2011-10-11
IL225207A (en) 2017-11-30
CY1124601T1 (el) 2022-07-22
US20150232479A1 (en) 2015-08-20
SI2465580T1 (sl) 2014-04-30
EP3045206B2 (de) 2023-02-15
KR20160003889A (ko) 2016-01-11
DK3187225T3 (da) 2022-02-28
US20130172559A1 (en) 2013-07-04
NO339525B1 (no) 2016-12-27
DK3284520T3 (da) 2019-09-16
SI3045206T1 (en) 2018-07-31
DK2465580T3 (en) 2014-03-10
FR14C0041I2 (fr) 2015-11-13
KR101504998B1 (ko) 2015-03-23
US9051337B2 (en) 2015-06-09
US20200339598A1 (en) 2020-10-29
MX2007013351A (es) 2008-01-21
LUC00210I2 (de) 2022-10-07
LT3045206T (lt) 2018-06-11
BRPI0610030B8 (pt) 2022-01-11
US20170260203A1 (en) 2017-09-14
US20170267693A1 (en) 2017-09-21
SI3284520T1 (sl) 2019-10-30
PL3372281T3 (pl) 2021-12-27
ES2667868T5 (es) 2023-06-01
NO20161315A1 (no) 2007-11-22
VN34404A1 (en) 2013-07-25
US20190284208A1 (en) 2019-09-19
PT3284520T (pt) 2019-09-10
NO2021018I1 (no) 2021-05-10
JP4295353B2 (ja) 2009-07-15
CA2606282C (en) 2016-04-26
KR20130133061A (ko) 2013-12-05
PT2465580E (pt) 2014-02-25
HUS2100022I1 (hu) 2021-07-28
EA200702080A1 (ru) 2008-04-28
US20170209454A1 (en) 2017-07-27
EP3372281A1 (de) 2018-09-12
ES2446324T3 (es) 2014-03-07
KR101580310B1 (ko) 2016-01-04
NL301109I1 (nl) 2021-09-15
WO2006116764A1 (en) 2006-11-02
PL3284520T3 (pl) 2020-01-31
JP2008540343A (ja) 2008-11-20
ES2667868T3 (es) 2018-05-14
US20120115875A1 (en) 2012-05-10
PL3045206T3 (pl) 2018-08-31
CY1116331T1 (el) 2017-02-08
US20160207939A1 (en) 2016-07-21
US20170224694A1 (en) 2017-08-10
CY2014024I2 (el) 2015-12-09
HK1249742A1 (zh) 2018-11-09
ES2743531T3 (es) 2020-02-19
US11267823B2 (en) 2022-03-08
SI3372281T1 (sl) 2021-11-30
DK3372281T3 (da) 2021-09-27
US20170253616A1 (en) 2017-09-07
KR20140097438A (ko) 2014-08-06
DK1874117T3 (da) 2013-09-23

Similar Documents

Publication Publication Date Title
LU92446I2 (fr) Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium
LU93327I2 (fr) Opicapone ou un sel pharmaceutiquement acceptable de celui-ci
LU92568I2 (fr) Siméprévir, ou un sel de celui-ci, y compris le sodium siméprévir
LU92702I2 (fr) Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig)
NO2023047I1 (no) Cedazuridine, or a pharmaceutically acceptable salt thereof
NO2022057I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
LU92137I2 (fr) Ruxolitinib, ou un de ses sels pharmaceutiquement acceptables
LU92883I2 (fr) Sonidégib ou un sel, hydrate ou solvate pharmaceutiquement acceptable qui en dérive
LU93180I2 (fr) Alirocumab ou un dérivé pharmaceutiquement acceptable de celui-ci (PRALUENT)
FIC20240007I1 (fi) Gefapiksantti tai sen farmaseuttisesti hyväksyttävä suola
LU93312I2 (fr) Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate
NL301106I1 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
LU92785I2 (fr) Céritinib ou un sel pharamceutiquement acceptable de celui-ci
NO2018016I2 (no) Niraparib eller et farmasøytisk akseptabelt salt, stereoisomer eller tautomer derav
NL300703I2 (nl) Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium.
NO2013008I1 (no) Krizotinib eller et farmasøytisk akseptabelt salt,hydrat eller solvat derav
LU92512I2 (fr) Afoxolaner, ou un oxyde nitrique de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci
NO2022022I1 (no) Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate
NO2016016I1 (no) Lesinurad, eller et farmasøytisk akseptabelt salt derav
LU91962I2 (fr) Azilsartan medoxomil (INN) et un de ses sels pharmaceutiquement acceptable, y compris le sel de potassium
GB0624471D0 (en) Merocyanine Derivatives
NL1031741A1 (nl) Purinederivaten.
IL190608A0 (en) 5-(arylsulfonyl)-pyrazolopiperidines